Gene: KLK1
Official Full Name: kallikrein 1provided by HGNC
Gene Summary: Kallikreins are a subgroup of serine proteases having diverse physiological functions. Growing evidence suggests that many kallikreins are implicated in carcinogenesis and some have potential as novel cancer and other disease biomarkers. This gene is one of the fifteen kallikrein subfamily members located in a cluster on chromosome 19. This protein is functionally conserved in its capacity to release the vasoactive peptide, Lys-bradykinin, from low molecular weight kininogen. [provided by RefSeq, Jul 2008]
Catalog Number | Product Name | Species | Gene | Passage ratio | Mycoplasma testing | Price |
---|---|---|---|---|---|---|
KO36923 | KLK1 Knockout cell line (HeLa) | Human | KLK1 | 1:3~1:6 | Negative | Online Inquiry |
KO36924 | KLK1 Knockout cell line (HCT 116) | Human | KLK1 | 1:2~1:4 | Negative | Online Inquiry |
KLK1 Gene Knockout Cell Lines are meticulously engineered cellular models that have had the kallikrein 1 (KLK1) gene specifically disrupted or deleted. These knockout cell lines serve as crucial tools for understanding the functional implications of KLK1 in various biological processes, including inflammation, blood pressure regulation, and tissue remodeling. Through targeted gene editing techniques, such as CRISPR-Cas9, the precise removal of the KLK1 gene allows researchers to elucidate its role in health and disease.
The primary mechanism by which KLK1 knockout cell lines operate involves the lack of expression of the KLK1 protein, a serine protease known for its diverse physiological roles. By comparing these knockout models with their wild-type counterparts, researchers can analyze downstream signaling pathways and cellular responses mediated by KLK1, leading to enhanced understanding of its contribution to pathophysiological states, such as cardiovascular diseases and cancer.
The scientific importance of KLK1 knockout cell lines is evident in their application in research settings aimed at drug discovery and development, as well as therapeutic interventions targeting KLK pathway modulation. In clinical settings, they can provide insights into novel biomarkers for disease progression or therapeutic efficacy in patients exhibiting aberrant KLK1 activity.
Compared to alternative models, such as overexpressing KLK1 or utilizing non-specific inhibitors, KLK1 knockout cell lines offer unparalleled specificity and reproducibility. They facilitate a direct assessment of gene function without the confounding factors that may arise from these other methodologies.
For researchers and clinicians alike, the value of KLK1 Gene Knockout Cell Lines lies in their ability to accelerate discovery in molecular biology while enhancing the understanding of KLK1-related pathologies. As a company dedicated to advancing scientific innovation, we bring years of expertise in developing high-quality biological products that empower researchers globally to achieve breakthrough discoveries.
Please note that all services are for research use only. Not intended for any clinical use.
If your question is not addressed through these resources, you can fill out the online form below and we will answer your question as soon as possible.
There is no product in your cart. |
CD Biosynsis is a leading customer-focused biotechnology company dedicated to providing high-quality products, comprehensive service packages, and tailored solutions to support and facilitate the applications of synthetic biology in a wide range of areas.